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The androgen receptor, like other nuclear receptors, activates target
genes by binding to hormone-responsive enhancers. Here we dem-
onstrate that androgen induces robust recruitment of androgen
receptor, members of the p160 coactivator family, and CREB-binding
proteinp300 specifically at the distant enhancer of prostate-specific
antigen (PSA) gene. Unexpectedly, we found that RNA polymerase II
(Pol II) is directly recruited to the enhancer in a hormone-dependent
manner, independent of the proximal promoter, and that the isolated
PSA enhancer can mediate efficient androgen induction of transcrip-
tion. Inhibition of the Pol II carboxyl-terminal domain kinase activity
with low concentrations of flavopiridol blocks Pol II transfer from the
enhancer to the promoter and selectively abolishes PSA induction by
androgen. Moreover, elevated levels of the p160 coactivator ACTR
AIB1 increase both androgen-dependent and -independent PSA ex-
pression, by facilitating Pol II recruitment to the enhancer. These
results support a model in which nuclear receptors and their coacti-
vators mediate hormone induction by serving as a staging platform
for Pol II recruitment.
Androgen is a key regulator of cell growth and differentiationin male sexual development and function as well as in
the progression of prostate cancer. These hormonal effects
are mediated by the androgen receptor (AR), a member of the
nuclear receptor superfamily, which consists of ligand-
dependent transcription factors (1). Recently, a growing number
of nuclear proteins have been found to associate with AR and are
postulated to mediate transcriptional control by the receptor (2,
3). Among them are members of the p160 coactivator family,
including SRC-1, TIF2GRIP1, and ACTR (AIB1RAC3
TRAM1pCIP). The p160 coactivators associate with nuclear
receptors in a hormone-dependent fashion primarily through
the central receptor–interaction domain that harbors several
LXXLL motifs.
Although p160 coactivators possess intrinsic histone acetylase
(HAT) activities, they are also capable of recruiting other HAT
proteins such as CREB-binding protein (CBP), p300, and PCAF
(4, 5), and the nuclear protein arginine methyltransferases
CARM1 and PRMT (6, 7). Both the acetylases and methylases
can regulate transcription by modifying nucleosomal and non-
nucleosomal nuclear proteins (7, 8). However, how the p160
coactivators promote RNA polymerase II (Pol II) transcription
is still not well understood. Domain mapping experiments
suggest that transactivation by the p160 coactivators is largely
attributable to their recruitment of CBPp300 and the HAT
activities (4, 9–12). Although earlier experiments indicate that
CBPp300 may interact directly with the Pol II complex (13, 14),
this notion lost currency with the discovery of the importance of
the HAT activity in transcriptional activation and the more
recent demonstration that the simple recruitment and assembly
of Pol II machinery in mammalian cells is not sufficient for
productive transcription (15, 16).
Previously, we and others demonstrated that hormone induces
histone hyperacetylation at the proximal promoters of nuclear
receptor target genes presumably through the recruitment of
p160 and p300CBP coactivator complexes (8, 17). To further
understand the molecular underpinnings of hormone induction
of gene expression, we analyzed androgen-induced recruitment
of AR and its associated coactivators to the entire 5 regulatory
region of the prostate-specific antigen (PSA) gene in hormone-
responsive LNCaP cells. High-level androgen induction of PSA
expression is conferred by an enhancer centered at4.2 kb on
the PSA gene, which contains multiple tandem androgen re-
sponse elements (18–20). Here, we show that on androgen
stimulation, the p160 and CBPp300 coactivators are preferen-
tially recruited to the enhancer. This observation has led to our
unexpected finding that Pol II is directly recruited to the
enhancer in an androgen-dependent manner and that Pol II
carboxyl-terminal domain (CTD) kinase activities are critical for
the possible tracking of Pol II from enhancer to promoter.
Materials and Methods
Chromatin Protein Association Assays. Chromatin immuno-
precipitation (ChIP) assay was performed with LNCaP cells
cultured in hormone-depleted medium for at least 3 days before
treatment with ligands. In vitro protein association assay with
immobilized reconstituted chromatin and details of the ChIP
procedures and materials used are provided in Supporting Text,
which is published as supporting information on the PNAS web
site, www.pnas.org.
Transient Transfection. LNCaP cells were transfected with lucif-
erase reporter pGL3-basic, or its derivatives with PSA upstream
sequences, pRL-SV40 Renilla luciferase, along with pCMX-
ACTR or pSh-CMV-TIF2, by using the Lipofectin reagent. Cells
were then treated with 10 nM 5-dihydrotestosterone (DHT) for
24 h before harvest for luciferase assay. The pGL3-PSA report-
ers were constructed by inserting restriction fragments of the
PSA upstream sequences with the indicated lengths as follows:
5.85-kb entire PSA upstream sequences, HindIII to HindIII;
630-bp PSA proximal promoter sequences, EcoRI to HindIII;
1.5-kb sequence containing the PSA enhancer, XbaI to
BamHI; and 2.0-kb fragment containing the PSA enhancer
and an immediate downstream sequence, XbaI to StuI.
Recombinant Adenovirus Vectors and Gene Expression Analysis.
ACTR cDNA was inserted into a modified pShuttle-CMV vector
with 3 hemagglutinin tag sequence at the C terminus. The
resulting constructs were used to generate recombinant adeno-
virus as described (8). Viruses were purified by centrifugation in
CsCl step gradients. Viral titers were determined by end-point
cytopathic effect assay with GFP adeno-vector as a reference.
Gene expression was compared by using RT-PCR. Total RNA
was prepared with the TRIzol reagent, and the cDNA was
synthesized with Moloney murine leukemia virus reverse tran-
scriptase. Gene-specific primers for the PCR are provided in
Supporting Text.
Abbreviations: AR, androgen receptor; PSA, prostate-specific antigen; Pol II, RNA polymer-
ase II; CTD, carboxyl-terminal domain; ChIP, chromatin immunoprecipitation; DHT, 5-
dihydrotestosterone; CBP, CREB-binding protein.
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Results
AR and p160-CBPp300 Coactivators Are Preferentially Recruited to
the PSA Enhancer on Androgen Stimulation. To investigate the role
of AR-associated coactivators in PSA induction, we first exam-
ined androgen-induced, endogenous AR and coactivator occu-
pancy over the entire 6-kb upstream regulatory region of PSA in
LNCaP cells by ChIP assay. For semiquantitative measurement
of the precipitated DNA, we used a panel of PCR primer pairs
with approximately equal efficiency to amplify partially over-
lapping fragments (300–500 bp) encompassing the 6-kb region
(Fig. 1A Top). The enhancer sequence was amplified as frag-
ments D, E, and F, whereas the sequence of proximal AREs and
initiation site was covered by fragments O and P. ChIP assay with
anti-AR antibody demonstrated clearly that, on androgen in-
duction, AR was strongly recruited to the enhancer region and
this AR occupancy persisted hours after DHT addition (Fig. 1 A,
-AR). Interestingly, the association of AR with the proximal
promoter was only marginal after DHT stimulation (Fig. 1 A and
Fig. 6, which is published as supporting information on the PNAS
web site). In the same experiments, we also measured the
recruitment of p160 coactivators and coregulators CBPp300.
Indeed, robust recruitment of ACTR, TIF2, and CBPp300 to
the PSA 5 regulatory region was observed when cells were
treated with DHT. Importantly, as seen for AR, androgen-
induced coactivator recruitment was highly restricted to the
enhancer (Fig. 1 A). Next, we transfected LNCaP cells with two
reporters containing either the 6-kb upstream sequence or the
630-bp proximal sequence of PSA. Results in Fig. 1B indicate
that the enhancer-containing 6-kb upstream sequence, not the
proximal promoter, was capable of mediating androgen induc-
tion. In agreement with the ChIP results, cotransfection of
coactivator ACTR and TIF2 constructs further potentiated
androgen-stimulated transcription through the 6-kb sequence,
but not the 630-bp promoter (Fig. 1B). Taken together, these
results suggest that the androgen-responsive enhancer of the
PSA gene mediates transcriptional activation through direct
recruitment of AR and the p160-CBPp300 coactivator complex.
Pol II Is Directly Recruited at PSA Enhancer, Independent of the
Proximal Promoter, on Androgen Induction. Transcription factors
and their coregulators are believed to regulate transcription, in
part, by controlling the recruitment andor assembly of the
general transcription machinery (16). We, therefore, examined
how Pol II is recruited to the upstream sequence of the PSA gene
in response to androgen stimulation. In agreement with our
previous results that hormones induce Pol II recruitment to the
promoters of estrogen receptor target genes (8), significant
recruitment of Pol II to the PSA promoter region is observed on
androgen induction (Fig. 2A, open bars). Intriguingly, strong
androgen-dependent Pol II cross-linking to the enhancer was
also detected. In fact, the DHT-induced Pol II cross-linking at
the enhancer is more abundant than that at the promoter (Fig.
2A, filled bars). This unexpected result prompted us to extend
the analysis to the other region of the PSA regulatory sequence.
As shown in Fig. 2B, remarkably, a significant level of Pol II
cross-linking was observed over the region between enhancer
and promoter. However, when regions further upstream were
analyzed, little Pol II occupancy was detected (Fig. 7, which is
published as supporting information on the PNAS web site).
An attractive model of how an enhancer influences the
function of the transcription machinery involves the physical
interactions of protein complexes assembled at the enhancer
with those at the promoter, leaving a DNA loop in between (i.e.,
the looping model). Formally, the cross-linking of Pol II to the
enhancer can be attributed either by the contact of protein
complexes formed at the enhancer with Pol II assembled at the
promoter or by the occupancy of Pol II at the enhancer
independent of promoter (Fig. 2C). The first scenario would
predict an efficient cross-linking of AR and p160-CBPp300
complex to the promoter sequence, which was not observed in
our analysis (Fig. 1). To further discern the two possibilities, we
took advantage of our observation that AR is recruited primarily
to the enhancer. If Pol II is directly recruited to the enhancer, it
would physically co-occupy the enhancer with AR. Therefore,
fragmented chromatin–protein adducts precipitated by anti-Pol
II antibody should contain the enhancer chromatin fragment
Fig. 1. AR and p160-CBPp300 coactivators are preferentially recruited to
the PSA enhancer to mediate androgen activation of PSA promoter in LNCaP
cells. (A) DHT induces the recruitment of AR and p160-CBPp300 coactivators
preferentially at the PSA enhancer. A diagram of the 6-kb upstream regula-
tory region of AR target gene PSA with androgen-responsive enhancer and
elements indicated above and the various fragments amplified in the ChIP
assay marked below as A to P. The amplification efficiency of the primer pairs
for the different fragments was assessed by PCR under the same cycling
condition by using two different volumes (1 and 4) of diluted LNCaP cell
genomic DNA prepared during the ChIP procedures. Indicated antibodies
were used to perform ChIP assay with LNCaP cells treated with 10 nM DHT for
30 min or 4 h, or mock-treated (C) for 4 h, to measure chromatin occupancy of
AR, ACTR, TIF2, and CBP along the 6-kb sequence of PSA. Input chromatin DNA
taken before immunoprecipitation from different samples was analyzed by
PCR and found to be identical (data not shown). (B) LNCaP cell transfection
was performed to analyze the ability of PSA enhancer andor promoter to
mediate androgen transcriptional induction and coactivation function. LNCaP
cells in hormone-depleted media were cotransfected with either the 630-bp
PSA proximal promoter-Luc reporter (a) or the 5.85-kb entire PSA upstream
regulatory sequence-Luc (b) and the ACTR or TIF2 expression plasmids. Trans-
fected cells were then treated with 10 nM DHT (filled bars) or mock-treated
(open bars) for 24 h before measuring luciferase activities.








that is also cross-linked with AR. As shown in Fig. 2D Left, when
the eluate of anti-Pol II precipitates were reprecipitated with
anti-AR antibody, indeed, the second precipitates contained the
enhancer DNA. In contrast, no significant amount of promoter
sequence can be detected, in accordance with the low occupancy
of AR at promoter. When the same eluate of Pol II precipitates
was reprecipitated with anti-Pol II antibody, strong hormone-
dependent cross-linkings were seen at both enhancer and pro-
moter, indicating that the failure to detect promoter sequence in
the anti-AR reimmunoprecipitation is not caused by the pref-
erential loss of promoter chromatin fragment during the elution.
Again, consistent with the notion that AR and Pol II co-occupy
enhancer but not promoter, a sequence from the enhancer but
not promoter was detected after the anti-AR precipitates were
subsequently immunoprecipitated with the Pol II antibody (Fig.
2D Right).
To determine whether the occupancy of Pol II at the enhancer
is independent of the promoter sequence of PSA, we incubated
the PSA enhancer chromatin assembled in vitro and immobilized
on beads with HeLa nuclear extract in the presence or absence
of purified AR, ACTR, and p300 proteins. After extensive
washing, proteins associated with the chromatin were detected
by Western blotting. Results in Fig. 2E show that both phos-
phorylated and unphosphorylated Pol II (top and bottom bands,
respectively, in lane 5) was recruited to the enhancer only in the
presence of DHT, and the AR, ACTR, and p300 proteins.
Interestingly, AR is recruited to the enhancer independent of
DHT. Taken together, these results indicate that, on androgen
stimulation, Pol II is directly recruited to the enhancer, inde-
pendent of the PSA promoter.
The Isolated Enhancer Mediates Strong Androgen Induction of Tran-
scription Independent of PSA Proximal Promoter. Our observation
that Pol II is directly recruited to the PSA enhancer on androgen
induction suggests that Pol II might function to initiate tran-
scription through the enhancer. To test this idea, we performed
transfection assay with promoterless reporter constructs con-
taining different PSA 5 upstream sequences. Remarkably, when
transfected into LNCaP cells, the reporter linked to a PSA 5
fragment containing essentially the core enhancer sequence
(construct 3) mediated a robust DHT-induced reporter gene
activity similar to the reporter that contains the entire 5 PSA
regulatory sequences (construct 1, Fig. 3). Surprisingly, however,
a similar reporter containing 500-bp extra sequences down-
stream of the enhancer (construct 4) was completely inactive in
Fig. 2. Pol II is directly recruited to the PSA enhancer on androgen stimula-
tion. (A) ChIP assay was performed with -Pol II antibody (N-20) to analyze the
Pol II occupancy at the enhancer (fragment E, filled bars) or the promoter
(fragment P, open bars) of the PSA gene. The relative amount of Pol II
occupancy in the presence versus absence of 10 nM DHT (fold induction) was
determined by quantifying the PCR products obtained from three experi-
ments. (B) Pol II occupancy over the entire PSA upstream regulatory sequence
was analyzed by using ChIP assay as in A with the monoclonal-Pol II antibody
8WG16. (C) Two possible modes of androgen-induced Pol II occupancy at the
PSA 5 regulatory region: Pol II is recruited to the enhancer and promoter
independently (Left) or Pol II is recruited to the promoter and physically
interacts with protein complex formed at the enhancer (Right). (D) Sequential
ChIP assay was used to analyze the association of Pol II and AR at the PSA
promoter (O and P) or the enhancer (E and F). LNCaP cells were treated with
10 nM DHT () or mock-treated () for 1 h before ChIP assay. Chromatin
fragments were first immunoprecipitated with -Pol II (Left) or -AR antibody
(Right). Immunocomplexes were eluted from the agarose beads and diluted
for a second immunoprecipitation for AR or Pol II occupancy analysis. (Ea)
Immobilized nucleosomal PSA enhancer fragment (4500 to 3750) was
incubated with HeLa nuclear extract (HNE), in the presence or absence of
purified AR, ACTR and p300 (AP) proteins shown in b, and DHT as indicated,
followed by extensive washes and Western blotting with indicated antibodies.
(b) Coomassie staining of purified AR (100 ng), ACTR (500 ng), and p300
(500 ng) proteins.
Fig. 3. The PSA enhancer, in isolation, mediates androgen induction of
transcription independent of PSA proximal promoter. Transient transfection
was performed as in Fig. 1B with the promoterless pGL3 basic-Luciferase
reporter, the 5.85-kb PSA upstream regulatory sequence linked to the Luc
(lane 1), the 630-bp PSA proximal promoter-Luc (lane 2), the 1.5-kb sequence
containing the PSA enhancer-Luc (lane 3), or the 2.0-kb fragment containing
the PSA enhancer and immediate downstream sequence (lane 4). Transfected
cells were treated with 10 nM DHT (filled bars) or mock-treated (open bars) for
24 h before measuring luciferase activities. RLU, relative luciferase unit.
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response to DHT induction, suggesting that at least part of the
enhancer function is controlled by an enhancer-context-
dependent mechanism. By Northern analysis with a 1.5-kb
fragment containing the enhancer sequence as a probe, we were
unable to detect any mature transcripts initiated around the
enhancer region in DHT-treated LNCaP cells (data not shown),
indicating that the enhancer does not serve as a gene promoter
in its natural chromatin context. Nevertheless, these results
suggest that the androgen-responsive enhancer of the PSA gene
not only can independently recruit Pol II, but also has the
potential to mediate transcription.
Pol II CTD Phosphorylation Is Important in Mediating Pol II Transfer
from the Enhancer to Promoter. Phosphorylation of Pol II CTD at
serines 5 and 2 of the heptad repeats is important in multiple
stages of transcription, particularly the transition of Pol II
function from promoter arrest to elongation (21). We thus
examined whether Pol II–CTD phosphorylation could play a role
in the conversion of Pol II recruited at the enhancer to the one
functioning at the promoter. To this end, we resorted to the CTD
kinases inhibitor flavopiridol (22, 23). We first analyzed the
effect of flavopiridol on androgen-induced PSA expression by
Pol II. Consistent with the previous reports that low concentra-
tion (200 nM) of flavopiridol does not show inhibitory effect
on most gene transcription (23), expression of AR itself and cell
cycle genes such as Cdk 4 and cyclin D was not significantly
affected by the treatment with 100 nM flavopiridol. In contrast,
under the same condition, DHT-induced PSA transcription was
completely blocked (Fig. 4A). We then examined the effect of
flavopiridol treatment on androgen-induced Pol II recruitment
occupancy at PSA gene (Fig. 4B). Strikingly, treating cells
simultaneously with DHT and flavopiridol strongly inhibited
androgen-induced Pol II recruitment at the promoter while
increasing the Pol II occupancy at the enhancer. Further analyses
with antibodies recognizing Pol II phosphorylated at CTD Ser-2
and Ser-5 indicate that the decrease of recruitment in Ser-2
phosphorylated Pol II accounts largely for the overall decrease
of Pol II recruitment at PSA promoter by flavopiridol treatment
(Fig. 4B). This effect was not seen at the promoter of other genes
whose expression was not affected by the low concentration of
flavopiridol (data not shown). Because blocking transcriptional
initiation or elongation would leave more Pol II assembled and
stalled at the promoter, as demonstrated for the IL-8 gene (24),
the decrease in Pol II occupancy of the PSA promoter by
flavopiridol cannot be attributed to the blockade of transcription
initiation or elongation at the promoter. Our finding that
decreased Pol II occupancy at the promoter is accompanied by
its simultaneously increased presence at the enhancer suggests
that Pol II recruited at the enhancer of PSA transfers to the
promoter and that flavopiridol perturbs this process by inhibiting
CTD kinase activity.
ACTR Mediates Androgen Induction of PSA Through Facilitating Pol II
Recruitment at Enhancer. Because p160 coactivators ACTR and
TIF2 are recruited primarily at the enhancer of PSA (Fig. 1), we
decided to test the hypothesis that p160 coactivators might play
a role in androgen-induced Pol II recruitment at the enhancer by
ectopically expressing ACTR in LNCaP cells (Fig. 5A). When
LNCaP cells were stimulated with a suboptimal concentration of
DHT (1 nM), increasing the level of ACTR significantly en-
hanced both androgen-dependent and -independent PSA ex-
pression (Fig. 5B). Importantly, a marked increase in Pol II
recruitment was detected by ChIP assay at the enhancer but not
the promoter in cells with elevated level of ACTR (Fig. 5C).
These results provide the evidence that p160 coactivators such
as ACTR are involved in androgen induction of PSA expression
by facilitating Pol II recruitment to the enhancer.
Discussion
Enhancers are discrete DNA elements that mediate the tran-
scriptional activation of DNA binding transcription factors at a
Fig. 4. CTD kinases are involved in possible Pol II transfer from enhancer to
promoter and androgen induction of PSA. (A) Flavopiridol selectively blocks
DHT induction of PSA expression measured by RT-PCR. RNA was isolated from
LNCaP cells treated with either 10 nM DHT or DHT plus 100 nM flavopiridol
(DHTFlavo) for the indicated times. (B) Flavopiridol blocks possible Pol II
transfer from enhancer to promoter. LNCaP cells were treated as in A for the
indicated times. ChIP assay using -Pol II 8WG16 (recognizes nonphosphory-
lated and phosphorylated Pol II), H5, and H14 (recognize Pol II CTD phosphor-
ylated at Ser-2 and Ser-5, respectively) was performed as in Fig. 2A to analyze
the occupancy of the different phosphorylated forms of Pol II at the enhancer
and the promoter.
Fig. 5. ACTR mediates PSA transcription by increasing Pol II recruitment at
the PSA enhancer. (A) LNCaP cells were infected with adenovirus vector
expressing ACTR at different multiplicities of infection (mois) (10, 100, and
200). Whole-cell lysates were prepared 48 h after infection and analyzed by
Western blot with antibodies against ACTR (BD Biosciences, San Diego) or
-actin. (B) RT-PCR was performed to measure PSA and -actin expression in
LNCaP cells infected with adeno-GFP or adeno-ACTR vectors at different mois
and treated with 1 nM DHT for the indicated times before harvest. (C)
Elevation of ACTR expression promotes Pol II recruitment to the PSA enhancer.
Pol II occupancy at PSA enhancer and promoter was analyzed by ChIP assay
with 8WG16 antibody. LNCaP cells were harvested 2 days after infection with
adenovirus vectors at moi 100 for either GFP (open bars) or WT ACTR (filled
bars) and treated with 1 nM DHT for the indicated times. C, without treatment.








distance from the promoter. It has long been speculated that
enhancers may function as an entry site for RNA polymerase to
relay the transcriptional activation signals impinged at the
enhancer to the nearby promoter (25). By analyzing the occu-
pancy of Pol II as well as AR and its coactivators over the entire
PSA regulatory region, we found that androgen induces the
recruitment of Pol II preferentially to the enhancer. We then
demonstrated that AR and Pol II co-occupy strongly at the
enhancer but not at the proximal promoter, thereby defying the
explanation by the simple looping model in which the enhancer
indirectly contacts Pol II complex assembled at the promoter.
With highly focused analysis, Shang et al. (26) recently reported
the detection of androgen-induced Pol II association with both
PSA promoter and enhancer (26). Although their study did not
address the molecular nature of such association, their result is
consistent with our conclusion that Pol II is directly recruited at
the enhancer. More strikingly, using in vitro reconstituted nu-
cleosomal PSA enhancer DNA immobilized on the beads, we
obtained results showing unequivocally that Pol II can be
recruited to the enhancer independent of the promoter and that
the Pol II recruitment at the enhancer entirely depends on the
presence of DHT and the purified AR, ACTR, and p300
proteins. Further, the CTD kinase inhibitor flavopiridol pro-
moted Pol II occupancy at the enhancer, with a concomitant
block of Pol II occupancy at the promoter. Taken together, these
results suggest that the recruitment of Pol II at the enhancer and
the promoter may be controlled by distinct mechanisms. Re-
cently, using ChIP assay, it was demonstrated that Pol II
occupancy at the locus control region of -globin genes is
regulated by an unidentified mechanism that may differ from
that at the -globin promoter (27). Our finding that, on hormone
induction, Pol II is recruited at a conventional enhancer suggests
that direct Pol II recruitment may represent a general mecha-
nism underlying enhancer function.
Conceptually, transcription factors and their coactivators or
Pol II recruited at a distant enhancer could act on the promoter
by either the looping mechanism or tracking along the chromatin
(28). Enhancers in mammalian cells are often 5 or 10 kb away
from their cognate promoters. Thus, it is less likely that protein–
protein contact between enhancer and promoter is achieved
simply by looping out the interval DNA. We tend to favor the
‘‘facilitated tracking’’ mechanism for the Pol II complex to
interact with the promoter, based on the observations made in
this study. Thus, we found that androgen-induced Pol II cross-
linking appears to trail over the entire region of the 6-kb PSA
upstream sequence. Intriguingly, the pattern of androgen-
induced histone hyperacetylation resembles the pattern of Pol II
cross-linking (data not shown). It is conceivable that the hyper-
acetylation of nucleosomal histones might help the transient
association of Pol II with chromatin downstream of the en-
hancer. In this regard, it is tempting to postulate that one of the
functions of Pol II CTD phosphorylation might be to facilitate
the association of Pol II complex with chromatin remodeling
factors.
In an attempt to assess directly the role of p160 coactivators
in AR-mediated induction of gene expression, we observed that
elevating ACTR level in prostate cancer cells could result in
marked increase of both androgen-dependent and -independent
PSA expression. Prostate cancer almost inevitably progresses
from a hormone-dependent to a hormone-refractory state with
elevated levels of PSA. Therefore, a thorough understanding of
the mechanism that governs the expression of PSA will shed light
on the mechanism underlying the androgen independence of
prostate cancer. Recently, aberrant expression of p160 coacti-
vators was identified in multiple human malignancies including
prostate cancer (29). It would be of interest to study the
involvement of p160 coactivators in the development of prostate
cancer androgen independence.
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